RecruitingPhase 4NCT07719894

Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes

Comparison of Efficacy and Safety Between Aspirin and Cilostazol on Cardiovascular Event in Patients at High Risk of Cardiovascular Disease, Randomization.

Sponsor

Seoul National University Bundang Hospital

Enrollment

1,200 participants

Start Date

May 6, 2026

Study Type

INTERVENTIONAL

Conditions

Atherosclerosis Type 2 Diabetes Mellitus (T2DM)

Summary

Patients with type 2 diabetes and cardiovascular risk factors are at increased risk of cardiovascular events. Therefore, a multi-center prospective randomized study will be conducted to compare the efficacy and safety of cilostazol and aspirin for the prevention of major adverse cardiac and cerebrovascular events (MACCE) in high-risk patients with type 2 diabetes.

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Aspirin and a drug called Cilostazol for people with atherosclerosis and type 2 diabetes mellitus (t2dm). The study is currently recruiting participants at 1 location. People eligible for this study include aged 19 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.